Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent Influenza Virus Split Vaccine in Children Aged 3-8 Years
NCT05138705Phase 4Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Dec 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of influenza virus vaccine, quadrivalent, split virion in influenza, sponsored by Shanghai Institute of Biological Products. Started Dec 2021; status: completed.
02
Drugs
influenza virus vaccine, quadrivalent, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05138705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138705.